Practical guide for the use of immunobiologic agents in allergic diseases - ASBAI

Os anticorpos monoclonais so uma nova classe de medicamentos que representa um marco na evoluo da terapia de doenas alrgicas graves. Alm de possibilitar uma terapia imunolgica alvo especfico, proporciona maior controle de sintomas, reduo de exacerbaes, melhoria da qualidade de vida e da segurana. A eficcia e a segurana dos anticorpos monoclonais no tratamento de doenas alrgicas esto bem documentadas nos estudos clnicos pivotais, de extenso e de vida real. No Brasil, esto licenciados atualmente pela Agncia Nacional de Vigilncia Monoclonal antibodies are a new class of drugs that represent a milestone in the evolution of therapy for severe allergic diseases. In addition to allowing targeted immunologic therapy, they can improve symptom control, reduce exacerbations, and increase quality of life and safety. The efficacy and safety of monoclonal antibodies in the treatment of allergic diseases are well documented in pivotal, extension, and real-life clinical studies. In Brazil, immunobiologic agents are currently licensed by the National Health Surveillance Agency (ANVISA) for use in asthma, atopic dermatitis (AD),